Analysts' Top 5 Price Targets of December 16, 2025
Reading Time: 4 minutes
KalVista Pharmaceuticals [US4834971032] Bank of America confirms Buy rating and adjusts the price target from $29 to $30 (80% upside potential) The optimistic assessment is based on the promising early performance of the new oral on-demand therapy Ekterly for HAE patients. The market launch has been very positively received - over 10% of HAE patients received a prescription within the first four months. By the end of the year, around 15% of patients are expected to have tried Ekterly . The management of KalVista is optimistic...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
